Alfred K. Lam

A phase II trial of chemotherapy-free neoadjuvant camrelizumab plus apatinib for resectable HNSCC: pathological response and vascular-immune crosstalk

Abstract Purpose: To evaluate the efficacy, safety, and tumour microenvironment remodelling of neoadjuvant camrelizumab plus apatinib in resectable head and neck squamous cell carcinoma (HNSCC; stage II–IVA). Materials and Methods: In this single-arm, exploratory phase II trial (...